HCA Healthcare starts 2025 strong on patient growth and operational efficiency

Overview

HCA Healthcare reported a strong start to 2025, delivering solid revenue and profit growth, driven by increased admissions, rising emergency room visits, and disciplined operational management.

CEO Sam Hazen noted: “The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025. As we look to the rest of the year, we remain encouraged by our performance, the overall backdrop of growing demand for healthcare services, and the investments we’ve made across our networks to serve our communities better.”

Q1 2025 vs. Q1 2024:

• Total revenue rose to $18.32bn (+5.7% YoY), driven by higher same facility admissions (+2.6% YoY), equivalent admissions (+2.8% YoY), and higher revenue per equivalent admission (+2.9% YoY).
  • Same facility admissions increased +2.6% YoY, reflecting steady growth in patient demand for acute care services.
  • Equivalent admissions +2.8% YoY, supported by higher overall patient volumes across HCA’s facilities.
  • Emergency room visits grew +4.0% YoY, driven by broader access initiatives and seasonal trends.
  • Inpatient surgeries remained stable, up +0.2% YoY, showing resilience in core surgical procedures.
  • Outpatient surgeries declined  -2.1%, partially impacted by competitive outpatient settings and case mix shifts.
  • Revenue per equivalent admission improved +2.9%, benefiting from payer mix stability and pricing initiatives.
  • Occupancy rate increased to 76.9% (compared to 75.2% in Q1 2024), reflecting higher bed utilization and consistent volume recovery trends.
• GAAP net income recorded a value of $1.61bn (+1.2% YoY), slightly higher despite a tough comparison against Q1 2024, which included $201m in facility sale gains.
• Diluted EPS grew to $6.45 (+8.8% YoY), boosted by share repurchases, contributing to a lower diluted share count.
• Adjusted EBITDA also increased to $3.73bn (+11.3% YoY), supported by operational efficiencies, improved payer mix, and higher patient volumes.
• Operating cash flow declined to $1.65bn (-33% YoY), lower due to working capital fluctuations and timing of vendor payments.
• Capital expenditures were $991m (excluding acquisitions), focused on facility expansions, technology upgrades, and network investments.
• The company ended Q1 2025 with $1.06bn in cash and cash equivalents, maintaining a strong liquidity position.
• Total debt stood at $44.58bn, reflecting continued investment in growth initiatives and facility expansion.
• The company repurchased 7.76m shares during the quarter for $2.51bn, demonstrating an active capital return strategy.
• HCA’s remaining share repurchase authorization was $8.26bn as of March 31, 2025, providing flexibility for future buybacks. A quarterly dividend of $0.72 per share was declared, payable on June 30, 2025, reaffirming HCA’s commitment to shareholder returns.

HCA reaffirmed its full-year 2025 guidance, expecting revenues between $72.8bn and $75.8bn, net income attributable to HCA Healthcare between $5.85bn and $6.29bn, and Adjusted EBITDA between $14.3bn and $15.1bn. Diluted EPS is forecasted in the range of $24.05 to $25.85. The company’s guidance reflects assumptions of stable operating conditions, modest volume growth, continued payer mix stability, and excludes impacts from facility sales or other unusual items.

Even though HCA’s share price saw a slight decline after reporting its first quarter results this year, it has appreciated over +4% in the last week and is around the 50-day moving average, which, together with an RSI around 50, could give some pretty good signals for Wall Street investors. Also, since the beginning of 2025, HCA’s share price has increased by approximately +11.5%, despite the downward trend observed in the last quarter of 2024.

Author: Ionuț-Adrian Lazar